Barclays Forecasts Strong Price Appreciation for CVS Health (NYSE:CVS) Stock

CVS Health (NYSE:CVS) had its target price raised by investment analysts at Barclays from $71.00 to $73.00 in a report released on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the pharmacy operator’s stock. Barclays‘s target price would indicate a potential upside of 11.10% from the stock’s current price.

Several other equities analysts have also recently commented on CVS. StockNews.com cut shares of CVS Health from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. Truist Financial lowered their price target on shares of CVS Health from $67.00 to $60.00 and set a “buy” rating on the stock in a report on Monday, January 6th. UBS Group lowered their price target on shares of CVS Health from $62.00 to $59.00 and set a “neutral” rating on the stock in a report on Tuesday. Edward Jones upgraded shares of CVS Health from a “hold” rating to a “buy” rating in a report on Thursday, January 30th. Finally, Royal Bank of Canada lowered their price target on shares of CVS Health from $68.00 to $58.00 and set an “outperform” rating on the stock in a report on Friday, November 15th. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $70.28.

CVS Health Trading Down 1.0 %

NYSE CVS opened at $65.71 on Thursday. CVS Health has a twelve month low of $43.56 and a twelve month high of $80.75. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.59 and a current ratio of 0.80. The stock has a market cap of $82.68 billion, a price-to-earnings ratio of 16.68, a PEG ratio of 0.60 and a beta of 0.61. The firm’s 50 day moving average price is $50.90 and its two-hundred day moving average price is $56.01.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share for the quarter, topping the consensus estimate of $0.89 by $0.30. CVS Health had a net margin of 1.36% and a return on equity of 10.72%. Equities analysts anticipate that CVS Health will post 5.14 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of CVS. MidAtlantic Capital Management Inc. acquired a new position in CVS Health during the 3rd quarter worth $25,000. Ridgewood Investments LLC raised its position in shares of CVS Health by 255.7% during the fourth quarter. Ridgewood Investments LLC now owns 626 shares of the pharmacy operator’s stock valued at $28,000 after buying an additional 450 shares during the last quarter. Stonebridge Financial Group LLC acquired a new position in shares of CVS Health during the fourth quarter valued at about $28,000. Hopwood Financial Services Inc. acquired a new position in shares of CVS Health during the fourth quarter valued at about $29,000. Finally, Livelsberger Financial Advisory acquired a new position in shares of CVS Health during the third quarter valued at about $31,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.